ArticleLa Tunisie medicale
Burden of breast and gynecological cancers in Tunisia between 1990 and 2030: Trend and projection.
Article in La Tunisie medicale. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 0 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo describe the burden of breast and gynecological cancers in Tunisia in 2017, to analyze the trend between 1990 and 2017 and to performit's prediction by 2030.
methodsThis was a study using data estimated by the Institute for Health Metrics and Evaluation (IHME) for years of life by breast cancer and gynecological cancers: ovary, cervix and uterus (endometrium and other unspecified parts of the uterus) in Tunisia in 2017.The trend analysis of age standardized DALYrate between 1990 and 2017 was analyzed by using Join Point software.The projection of number of DALY and YLL by 2030 was conducted by SPSS software using Age-Period-Cohort (APC) models.
resultsIn 2017, the age standardized DALYs rate for breast and gynecological cancers was 538.5/100,000 women. Breast cancer proved observed the highest rate of standardized DALY rate with 378.5/100,000 women followed by ovarian cancer (rate standardized DALY=72.7/100,000 women).The standardized DALY rate increased between 1990 and 2017 except for cervix cancer and uterine cancer which have been on a downward trend. According to the same conditions between 1990 and 2017, the age standardized DALY rate in 2030 will reach 674.6/100,000 women (95% CI=667.2/100,000-682.1/100,000).
conclusionStrengthening prevention strategy against cancer in general and women's cancers in particularis strongly recommended to reduce cancer burden and to changeits trend.
Indexed as
Identifiers
35244922PMC8734482W4287400322What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.